Last mentioned: Mar 17, 2026
Valuation Period
Expected timeframe for determining the fair market value of the equity investment.
Palliative Care Findings
New research confirms high efficacy rates for mitigating end-of-life distress in oncology settings.
Option Exercised
PsyLabs officially triggers the put option, requiring an equity investment from PBM.
Put Option Exercised
PsyLabs Ltd. formally exercises its rights under the Put Option Agreement with Psyence BioMed.
Strategic Investment Announced
Psyence BioMed announces it will make an equity investment in PsyLabs at fair market value.
Put Option Established
Psyence BioMed and PsyLabs enter into a strategic put option agreement.
SAP Expansion
Canada formally expands the Special Access Program to include restricted psychedelic substances.
Canadian Exemptions
Health Canada grants the first legal exemptions for psilocybin use to four terminally ill patients.
FDA Breakthrough Status
FDA grants Breakthrough Therapy designation to psilocybin for treatment-resistant depression.
A new comparative study reveals that psychedelic-assisted therapy significantly exceeds the efficacy of standard nicotine patches for long-term smoking cessation. The findings suggest a paradigm shift in treating nicotine addiction, moving from continuous replacement to episodic, transformative intervention.
A landmark study has demonstrated that a single dose of psilocybin, paired with psychological support, significantly outperforms traditional nicotine replacement therapies for long-term smoking cessation. The findings suggest a paradigm shift in treating substance use disorders through psychedelic-assisted therapy.
Clinical research into psilocybin-assisted therapy is demonstrating significant potential in mitigating existential distress and depression among terminally ill patients. These findings are driving a re-evaluation of palliative care protocols and accelerating the push for expanded regulatory access to psychedelic-based treatments.
Psyence Biomedical Ltd. (Nasdaq: PBM) has announced a strategic equity investment in PsyLabs Ltd. after the manufacturer exercised its rights under a previously established put option agreement. This move strengthens the relationship between the biopharmaceutical developer and its primary supplier of nature-derived psychedelic compounds.
Psyence Biomedical Ltd. (Nasdaq: PBM) has confirmed a strategic equity investment in PsyLabs following the exercise of a pre-existing put option agreement. The transaction reinforces the vertical integration between the clinical-stage developer and its primary source of pharmaceutical-grade, nature-derived psychedelic compounds.
Psyence Biomedical Ltd. (Nasdaq: PBM) has confirmed a strategic equity investment in PsyLabs following the exercise of a previously established put option. This move deepens the integration between the biopharmaceutical developer and its primary manufacturer of pharmaceutical-grade psychedelic compounds.